Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3
| BFRI Stock | USD 0.98 0.04 3.92% |
Under 62% of Biofrontera's investor base is looking to short. The analysis of the overall investor sentiment regarding Biofrontera suggests that many traders are alarmed. Biofrontera's investing sentiment shows overall attitude of investors towards Biofrontera.
Biofrontera |
Filed transaction by Biofrontera Officer: Executive Chairman. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Biofrontera Fundamental Analysis
We analyze Biofrontera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofrontera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biofrontera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Biofrontera is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Biofrontera Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biofrontera stock to make a market-neutral strategy. Peer analysis of Biofrontera could also be used in its relative valuation, which is a method of valuing Biofrontera by comparing valuation metrics with similar companies.
Peers
Biofrontera Related Equities
| SHPH | Shuttle Pharmaceuticals | 1.67 | ||||
| PRFX | Painreform | 1.61 | ||||
| AKAN | Akanda Corp | 1.20 | ||||
| SXTC | China SXT | 0.22 | ||||
| CPIX | Cumberland Pharmaceuticals | 2.21 | ||||
| EVOK | Evoke Pharma | 4.51 | ||||
| RGC | Regencell Bioscience | 5.35 | ||||
| PROC | Procaps Group | 5.36 | ||||
| IXHL | Incannex Healthcare | 7.30 | ||||
| CPHI | China Pharma | 19.23 | ||||
| SBFMW | Sunshine Biopharma | 20.00 |
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |